In severe cases, it may cause difficulty breathing, necessitating immediate medical attention
As in Phase-I HSB, phosphocreatine was not detected in the plasma of Phase-II HSB
Overall, the available research suggests that treatment with intravenous or oral lipoic acid may help reduce symptoms of diabetic peripheral neuropathy
decreased appetite (7% vs 5%)
[1] [2] However, establishing a definitive causal relationship remains complex, as patients prescribed semaglutide often have underlying risk factors for pancreatitis, including obesity, hypertriglyceridemia, and metabolic syndrome
Clinical check-ins and symptom logs allowed clinicians to slow escalation rather than stop therapy, preserving continuity and reducing avoidable discontinuations